While traces of early research on cannabis exist, its prohibition in the United States in the 1930s led other countries to follow suit, thus causing a noticeable decades-long gap in the availability of cannabis research.
With such a gap in clinical research, the cannabis industry has had to rely on empirical data to understand cannabis. This empirical data -- the data created by collecting individual stories or experiences -- supported the cannabis movement through the end of prohibition in many areas across the globe. Now, clinical cannabis research can resume as legalization progresses.
Advancing Clinical Research on Cannabis and animals
Across North America, the EU, and research hotspots like Israel, clinical researchers are increasingly applying clinical data and research methods to understand cannabis’ efficacy on common conditions like pain, inflammation, and anxiety.
Since horses can’t communicate, how does human patient-generated data inform cannabis medicine for horses? This is where cannabis is precisely unique. Since the endocannabinoid system is present in all mammals, research that focuses on the ECS in both animal and human subjects helps advance knowledge of cannabis medicine as a whole.
CannaHorse has paired up with Strainprint, as well as researchers at Biopharm Research Institute in Prague to formulate and engage in clinical trials for products specific to horses based on patient-generated data and available clinical research. As an example, our Equilibrium product is a formulation that uses the data on CBD (cannabidiol), THC (delta-9 tetrahydrocannabinol), and minor cannabinoid CBN (cannabinol) to formulate a stable cannabinoid profile. Equilibrium also incorporates the terpenes linalool, myrcene, and limonene based on the same data sources for a plant-based support product with a formulation showing success for anxiety in humans.
Learn more about CannaHorse’s research and browse our cannabis education portal here.